NI 0801

Drug Profile

NI 0801

Alternative Names: Alpha-IP-10; NI-0801; α-IP-10

Latest Information Update: 02 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovImmune SA
  • Class Antiallergics; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic contact dermatitis; Primary biliary cirrhosis

Most Recent Events

  • 19 Feb 2014 Phase II development in Primary biliary cirrhosis is ongoing in Europe
  • 05 Sep 2011 Phase-II clinical trials in Primary biliary cirrhosis in Italy (Parenteral)
  • 05 Sep 2011 Phase-II clinical trials in Primary biliary cirrhosis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top